CYP2C9 Cancer Research Results
CYP2C9, CYP2C9: Click to Expand ⟱
| Source: |
| Type: |
CYP2C9, cytochrome P450 enzyme
– CYP2C9 is involved in the metabolism of a range of xenobiotics, including several anticancer drugs, which can affect drug efficacy and toxicity.
– Although CYP2C9 is not traditionally considered an oncogene or tumor suppressor, its expression and genetic variants can influence patient responses to chemotherapy.
|
Scientific Papers found: Click to Expand⟱
*BioAv↓, We find that oral intake of dietary materials would require heroic ingestion amounts and is not feasible. However, use of supplements of semi-purified apigenin in capsule form could reach target blood levels using amounts that are within the range cu
Half-Life∅, elimination half-life (T1/2) averaging 2.52 ± 0.56h
*BioAv↓, bioavailability is in the region of 30%
Dose∅, Blood and urine samples were taken following a meal consisting of 2g parsley/kg body weight–which was equivalent to ∼17mg of apigenin -> 28–337nmol/L at 6–10h after consumption
eff↑, Apigenin and quercetin enhance their own and each other’s bioavailability by downregulating the activity of ABC transporters
CYP1A2↓, status of apigenin as an inhibitor of CYP1A2, CYP2C9 and CYP3A4
CYP2C9↓,
CYP3A4↓,
P450↓, Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
CYP3A4↓, B. monnieri reduced the catalytic activities of CYP3A4, CYP2C9 and CYP2C19 to less than 10% compared to the total activity (without inhibitor = 100%).
CYP2C9↓,
CYP2C9↓, chrysin conjugates are strong inhibitors of certain biotransformation enzymes (e.g., CYP2C9) and transporters (e.g., OATP1B1, OATP1B3, OATP2B1, and BCRP) examined.
OATPs↓,
ABCG2↓,
BioEnh↝, simultaneous administration of chrysin-containing dietary supplements with medications needs to be carefully considered due to the possible development of pharmacokinetic interactions.
*AntiCan↑, Isobavachalcone, a naturally occurring chalcone in Psoralea corylifolia, posses many biological properties including anticancer, antiplatelet, and antifungal.
*AntiAg↑,
*AntiFungal↑,
CYP2C9↓, isobavachalcone demonstrated broad-spectrum inhibitory effects against CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, UGT1A1, UGT1A9, UGT2B7 with IC50 values of 1.08-9.78 μM.
UGT1A↓,
CYP2D6↓,
CYP2E1↓,
Showing Research Papers: 1 to 4 of 4
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
CYP2D6↓, 1, UGT1A↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
CYP2E1↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
CYP3A4↓, 2,
Barriers & Transport(tgid=15) ⓘ
OATPs↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
ABCG2↓, 1, BioEnh↝, 1, CYP1A2↓, 1, CYP2C9↓, 4, Dose∅, 1, eff↑, 1, Half-Life∅, 1, P450↓, 1,
Total Targets: 13
Pathway results for Effect on Normal Cells:
Migration(tgid=13) ⓘ
AntiAg↑, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 2,
Functional Outcomes(tgid=23) ⓘ
AntiCan↑, 1,
Infection & Microbiome(tgid=24) ⓘ
AntiFungal↑, 1,
Total Targets: 4
Scientific Paper Hit Count for: CYP2C9, CYP2C9
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1130 State#:% Dir#:1
wNotes=on sortOrder:rid,rpid
Home Page